790 related articles for article (PubMed ID: 31712207)
1. Meropenem-Vaborbactam Activity against Carbapenem-Resistant
Castanheira M; Doyle TB; Kantro V; Mendes RE; Shortridge D
Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31712207
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme.
Pfaller MA; Huband MD; Mendes RE; Flamm RK; Castanheira M
Int J Antimicrob Agents; 2018 Aug; 52(2):144-150. PubMed ID: 29510189
[TBL] [Abstract][Full Text] [Related]
3. Meropenem-Vaborbactam Activity against U.S. Multidrug-Resistant
Shortridge D; Kantro V; Castanheira M
Microbiol Spectr; 2023 Feb; 11(1):e0450722. PubMed ID: 36622238
[TBL] [Abstract][Full Text] [Related]
4. Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals.
Castanheira M; Doyle TB; Deshpande LM; Mendes RE; Sader HS
Int J Antimicrob Agents; 2021 Nov; 58(5):106439. PubMed ID: 34547421
[TBL] [Abstract][Full Text] [Related]
5. Effects of KPC Variant and Porin Genotype on the
Wilson WR; Kline EG; Jones CE; Morder KT; Mettus RT; Doi Y; Nguyen MH; Clancy CJ; Shields RK
Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30617090
[TBL] [Abstract][Full Text] [Related]
6. In vitro evaluation of meropenem-vaborbactam against clinical CRE isolates at a tertiary care center with low KPC-mediated carbapenem resistance.
Kinn PM; Chen DJ; Gihring TM; Schulz LT; Fox BC; McCreary EK; Lepak AJ
Diagn Microbiol Infect Dis; 2019 Mar; 93(3):258-260. PubMed ID: 30344065
[TBL] [Abstract][Full Text] [Related]
7. Meropenem-Vaborbactam Tested against Contemporary Gram-Negative Isolates Collected Worldwide during 2014, Including Carbapenem-Resistant, KPC-Producing, Multidrug-Resistant, and Extensively Drug-Resistant Enterobacteriaceae.
Castanheira M; Huband MD; Mendes RE; Flamm RK
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28652234
[TBL] [Abstract][Full Text] [Related]
8. Meropenem/vaborbactam: a next generation β-lactam β-lactamase inhibitor combination.
Novelli A; Del Giacomo P; Rossolini GM; Tumbarello M
Expert Rev Anti Infect Ther; 2020 Jul; 18(7):643-655. PubMed ID: 32297801
[TBL] [Abstract][Full Text] [Related]
9. Activity of meropenem/vaborbactam and comparators against Gram-negative isolates from Eastern and Western European patients hospitalized with pneumonia including ventilator-associated pneumonia (2014-19).
Shortridge D; Carvalhaes C; Deshpande L; Castanheira M
J Antimicrob Chemother; 2021 Sep; 76(10):2600-2605. PubMed ID: 34302173
[TBL] [Abstract][Full Text] [Related]
10. Activity of meropenem/vaborbactam and comparators against non-carbapenemase-producing carbapenem-resistant Enterobacterales isolates from Europe.
Shortridge D; Deshpande LM; Streit JM; Castanheira M
JAC Antimicrob Resist; 2022 Oct; 4(5):dlac097. PubMed ID: 36196439
[TBL] [Abstract][Full Text] [Related]
11. Microbiology of Meropenem-Vaborbactam: A Novel Carbapenem Beta-Lactamase Inhibitor Combination for Carbapenem-Resistant Enterobacterales Infections.
Bhowmick T; Weinstein MP
Infect Dis Ther; 2020 Dec; 9(4):757-767. PubMed ID: 33017041
[TBL] [Abstract][Full Text] [Related]
12. Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae.
Lomovskaya O; Sun D; Rubio-Aparicio D; Nelson K; Tsivkovski R; Griffith DC; Dudley MN
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28848018
[TBL] [Abstract][Full Text] [Related]
13.
Nelson K; Rubio-Aparicio D; Sun D; Dudley M; Lomovskaya O
Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32482673
[TBL] [Abstract][Full Text] [Related]
14. Activity of aztreonam-avibactam against Enterobacterales resistant to recently approved beta-lactamase inhibitor combinations collected in Europe, Latin America, and the Asia-Pacific Region (2020-2022).
Sader HS; Carvalhaes CG; Kimbrough JH; Mendes RE; Castanheira M
Int J Antimicrob Agents; 2024 Apr; 63(4):107113. PubMed ID: 38354826
[TBL] [Abstract][Full Text] [Related]
15. Effect of the β-Lactamase Inhibitor Vaborbactam Combined with Meropenem against Serine Carbapenemase-Producing Enterobacteriaceae.
Castanheira M; Rhomberg PR; Flamm RK; Jones RN
Antimicrob Agents Chemother; 2016 Sep; 60(9):5454-8. PubMed ID: 27381386
[TBL] [Abstract][Full Text] [Related]
16. Activity of Imipenem-Relebactam and Meropenem-Vaborbactam against Carbapenem-Resistant, SME-Producing Serratia marcescens.
Biagi M; Shajee A; Vialichka A; Jurkovic M; Tan X; Wenzler E
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31932381
[TBL] [Abstract][Full Text] [Related]
17. Molecular characterization of intestinal carriage of carbapenem-resistant Enterobacteriaceae among inpatients at two Iranian university hospitals: first report of co-production of bla
Solgi H; Badmasti F; Aminzadeh Z; Giske CG; Pourahmad M; Vaziri F; Havaei SA; Shahcheraghi F
Eur J Clin Microbiol Infect Dis; 2017 Nov; 36(11):2127-2135. PubMed ID: 28639165
[TBL] [Abstract][Full Text] [Related]
18. Nacubactam Enhances Meropenem Activity against Carbapenem-Resistant Klebsiella pneumoniae Producing KPC.
Barnes MD; Taracila MA; Good CE; Bajaksouzian S; Rojas LJ; van Duin D; Kreiswirth BN; Jacobs MR; Haldimann A; Papp-Wallace KM; Bonomo RA
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182530
[TBL] [Abstract][Full Text] [Related]
19. Molecular characterization of carbapenem-resistant
Yan WJ; Jing N; Wang SM; Xu JH; Yuan YH; Zhang Q; Li AL; Chen LH; Zhang JF; Ma B; Ma Q; Li Y
J Med Microbiol; 2021 Mar; 70(3):. PubMed ID: 33587030
[No Abstract] [Full Text] [Related]
20. Meropenem-vaborbactam: a carbapenem and beta-lactamase inhibitor with activity against carbapenem-resistant Enterobacteriaceae.
Lee YR; Baker NT
Eur J Clin Microbiol Infect Dis; 2018 Aug; 37(8):1411-1419. PubMed ID: 29675787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]